Figure 1. Flow of Patients.

^aPatients were women with triple-negative breast cancer who received locoregional therapy but no chemotherapy from 13 participating institutions. Data were submitted from the 13 participating centers, which were located in North America (Rochester, Minnesota, USA; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and Genova, Italy; Gothenburg, Sweden), and Asia (Tokyo, Japan; Seoul, Korea).

^bNumber of cases included for each tumor-infiltrating lymphocyte (TIL) level: less than 30%, 1300 (66%); 30% to 49%, 249 (13%); 50% to 74%, 249 (13%); and 75% or greater, 168 (9%).